Log in
Enquire now
‌

US Patent 8961988 Compositions and methods for the treatment or prevention of hepatitis B virus infection

Patent 8961988 was granted and assigned to Globeimmune, Inc. on February, 2015 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Patent Applicant
Globeimmune, Inc.
Globeimmune, Inc.
Current Assignee
Globeimmune, Inc.
Globeimmune, Inc.
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
8961988
Date of Patent
February 24, 2015
Patent Application Number
14184481
Date Filed
February 19, 2014
Patent Citations Received
‌
US Patent 12128078 Lysates of recombinant yeast for inducing cellular immune responses
0
Patent Primary Examiner
‌
Agnieszka Boesen
Patent abstract

Disclosed are yeast-based immunotherapeutic compositions, hepatitis B virus (HBV) antigens, and fusion proteins for the treatment and/or prevention of HBV infection and symptoms thereof, as well as methods of using the yeast-based immunotherapeutic compositions, HBV antigens, and fusion proteins for the prophylactic and/or therapeutic treatment of HBV and/or symptoms thereof.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 8961988 Compositions and methods for the treatment or prevention of hepatitis B virus infection

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.